DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Tirzepatide (Zepbound). Adults with overweight or obesity, without type 2 diabetes.
Percent change in body weight at week 72.
Mean weight loss 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs 3.1% with placebo. 91.0% of patients on 15 mg lost ≥5%.
Adults with overweight or obesity, without type 2 diabetes.
Once-weekly subcutaneous tirzepatide 5, 10, or 15 mg vs placebo with lifestyle intervention.
Percent change in body weight at week 72.
Mean weight loss 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs 3.1% with placebo. 91.0% of patients on 15 mg lost ≥5%.
Jastreboff AM et al, NEJM 2022;387:205-216